If I had bought into Avacta (LSE: AVCT) five years ago, the value of my investment would have quadrupled. That is the sort of return many investors dream of. Have I missed the boat, or should I add some Avacta shares to my portfolio now?
Improving outlook
This week the company published its prelim results, and there were definitely some positive elements.
Revenue more than tripled. It is still fairly low at £9.6m, given that Avacta has a market capitalisation north of £300m. But the big jump reflected Avacta reaching certain milestones in its collaborative work with a couple of partners, resulting in cash payments. That suggests that the business is moving forward. Some of the revenue increase also resulted from the acquisition of a diagnostics company.
I see such developments as part of the foundation for longer-term revenue growth.
The company also reduced its adjusted loss before interest, tax, depreciation and amortisation (before non-cash and non-recurring items) by 30%.
But it is still substantial, at £15.1m. I also think that metric is so loaded with exclusions that it is not a useful measurement tool for an investor like me. The statutory loss from continuing operations moved up sharply, to almost £40m.
The company thinks that a “significant near-term value driver” will be clinical trials on the efficacy of a programme to reduce the systemic toxicities of some chemotherapy treatments. It announced yesterday that the first patient has been dosed in a US Phase One clinical study for that treatment.
Lots to prove
However, a lot rides on the ultimate outcome of those clinical trials. If they provide positive results of the treatment’s efficacy, I think Avacta shares could soar even from where they are today.
The reverse is also true, though. Failure in the costly trials could see the shares crash down to earth after their strong performance in recent years.
Meanwhile, cash burn is a concern for me. It ended last year with cash and cash equivalents of £42m. But cash has been going out the door fast. Last year, the business had operating cash outflows of £16m. Acquisition costs pushed investing net cash outflows to £25m.
The company has been able to raise cash. Selling more shares and bonds last year raised £61m, for example. But there is a risk of further shareholder dilution in future due to the company’s ongoing cash burn.
Are Avacta shares for me?
Given all this, it does not take me long to consider my own position as a potential investor.
I like the company’s prospects and, if clinical trial results are positive, reckon Avacta shares could keep soaring in coming years.
But the risks are simply too high for my tolerance, even if they are common when investing in biotech shares.
The company is heavily lossmaking. For now, a lot rides on a single product, concentrating the risk. There is no proven profitable model here yet, so I would be investing based on my hopes for the company’s drug pipeline, not its current performance.
That seems too risky for me. I shall not be purchasing any Avacta shares.
The post Avacta shares quadrupled in five years! Am I too late to buy? appeared first on The Motley Fool UK.
Don’t miss this top growth pick for the ‘cost of living crisis’
While the media raves about Google and Amazon, this lesser-known stock has quietly grown 880% – with a:
Greater than 20X increase in margins
Nearly 60% compounded revenue growth over 5 years – more than Apple, Amazon and Google!
A 3,000% earnings explosion
Of course, past performance is no guarantee of future results. However, we think it’s stronger now than ever before. Amazingly, you may never have heard of this company.
Yet there’s a 1-in-3 chance you’ve used one of its 250 brands. Many are household names with millions of monthly website visitors, and that often help consumers compare items, shop around and save.
Now, as the ‘cost of living crisis’ bites, we believe its influence could soar. And that might bring imminent new gains to investors who’re in position today. So please, don’t leave without your FREE report, ‘One Top Growth Stock from The Motley Fool’.
Claim your FREE copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#FFFFFF’);
})()
More reading
The Numis share price surged 67% today. I spy opportunity!
Will the ITV share price stay in pennies for long?
Should investors buy cheap Rolls-Royce shares in May?
My 3 top reasons to buy BT shares in 2023
Is property built on a strong platform?
C Ruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.